Medicago To Kick Off Large Study Of COVID-19 Vaccine With GSK Booster
A combination of Canadian drug developer Medicago's experimental COVID19 vaccine and a booster from Britain's GlaxoSmithKline will enter a large study with more than 30,000 volunteers this year, the two companies said on Thursday.
- Last Updated: November 12, 2020, 20:12 IST
- FOLLOW US ON:
A combination of Canadian drug developer Medicago’s experimental COVID-19 vaccine and a booster from Britain’s GlaxoSmithKline will enter a large study with more than 30,000 volunteers this year, the two companies said on Thursday.
The news comes days after early-stage data showed Medicago’s plant-based vaccine candidate produced virus-fighting antibodies in all volunteers.
The mid-to-late-stage clinical studies will test the safety and immune response capabilities of a regimen involving two doses of the vaccine with GSK’s pandemic adjuvant given 21 days apart.
Medicago has said a lower dose of the vaccine will be used for further trials, for which Dynavax Technologies’ adjuvant will not be used as before.
“Proven dose sparing and a high immune response due to GSK’s adjuvant make us confident of delivering an efficacious vaccine with an acceptable safety profile in collaboration with Medicago,” said Thomas Breuer, chief medical officer at GSK’s vaccines division.
In study groups of adults under the age of 65, five in six participants will be given the vaccine at random, in the smaller, mid-level, Phase II stage, whereas in groups with volunteers aged 65 or more, two in three will receive the vaccine.
The late-stage, Phase III part of the Medicago study will likely begin before the end of the year.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor